地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:18771997407
邮箱:sales@amyjet.com
<艾美捷科技代理CSCRIE Corporation品牌全系列产品
CSCRIE Corporation成立于2020年3月,公司致力于解决生命科学领域研究人员面临的问题,通过运用多年来积累的精密冲压技术、胶带与薄膜层压技术以及激光微加工技术,为生命科学市场提供各类产品。此外,CSCRIE公司还承接原创细胞培养板以及微流控芯片等带有微孔与微槽的产品的试制与开发。CSCRIE公司的产品包括样品过滤、标签与密封(多种应用),特种微孔板等产品。

▍CSCRIE产品线
● 样品过滤
CSCRIE的离心管用密封式滤器和96孔微孔板滤器可助您快速完成样品过滤。此外,其底部带滤网的96孔或384孔微孔板非常适合高通量筛选。
| 产品名称 | 产品描述 |
| Mesh seal for sample filtration (for 1.5 mL and 5 mL tubes) | This seal type mesh (strainer) is designed for rapid sample filtration on 1.5 mL and 5 mL tubes. |
| Mesh seal for sample filtration (for 15 mL tube) | This seal type mesh (strainer) is designed for rapid sample filtration on 15 mL tube. |
| Mesh seal for sample filtration (for 50 mL tube) | This seal type mesh (strainer) is designed for rapid sample filtration on 50 mL tube. |
| Mesh seal for sample filtration (for 96 well plate) | This seal type mesh (strainer) is designed for rapid sample filtration on 96 well plate. |
| Mesh bottom filtration plate (96- & 384-well plate) | This mesh bottom filtration plate is designed for rapid and highthrouput sample filtration from 96- or 384-well plate by centrifuge. |
● 标签与密封(多种应用)
| 产品名称 | 产品描述 |
| Sealing Film for real-time PCR | 低自体荧光压敏 PCR 板密封膜,兼容 PCR 和实时荧光定量 PCR (real-time PCR)。经 γ 射线灭菌,具备良好的耐热性(-20℃ 至 110℃)。 |
| Hydrophobic PDMS Sheet (Ultra-thin type) | 超薄高精度疏水性 PDMS(聚二甲基硅氧烷)薄膜,专注于活菌、活细胞及 DNA 的分析与培养。 |
| Hydrophilic PDMS Sheet | 具有持久亲水性的 PDMS 片材,适用于多种研究应用。 |
| Microplate note seal | 这是一款独特的密封膜,可在 96 孔微孔板上直接书写文字。 |
| Anti-Frost Label Protector | 防冻标签保护膜,可全面保护样品管上的标记,例如防霜冻、防乙醇等。 |
| Microplate seal for 96-well (cutting off type) | 微孔板封膜,可沿每行(8孔)的压痕线切割,便于在样本注入期间及之后反复开合。 |
● 特种微孔板
<| 产品名称 | 产品描述 |
| Microplate without bottom plate | 该微孔板无孔底部分,可根据研究应用需求在底部结合任意材料。其产品系列包括 6 孔、24 孔、96 孔及 384 孔规格。 |
● 其他产品
<| 产品名称 | 产品描述 |
| CS Mouse Wound Splint | CS 小鼠伤口夹板在与皮肤接触侧设有胶带层,因此固定夹板时无需额外使用粘合剂或胶水,与传统夹板相比,固定操作更便捷。 |
| CS IHC-Fencing Seal | 这是一种环绕载玻片上组织切片的疏水密封结构,可防止抗体、磷酸盐缓冲液(PBS)等试剂在组织标本上发生外溢或混合。 |
<艾美捷科技代理AxisPharm品牌全系列产品
AxisPharm是一家专业的分析服务提供商,致力于为科学研究界和工业界提供高质量的分析服务。凭借先进的仪器设备和专业的技术团队,AxisPharm在生物分析、化学分析和质量控制领域树立了良好的声誉。AxisPharm公司的产品线包括:PEG 连接子、用于药物递送的脂质、荧光染料、单击化学试剂、聚聚乙二醇,共聚物、可裂解的连接子、抗体和抗体药物偶联物ADC、ADC 有效载荷、细胞生物学试剂、脱氧核糖核酸、修饰语、探针、合成肽、目标特定链接器、硫醇反应性接头、酸反应性连接子、胺反应性连接子、羰基反应性连接子、探针、修饰符。

▍AxisPharm产品线
● PEG连接子:聚合物聚乙二醇是多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 用于药物递送的脂质:在药物递送系统中起着至关重要的作用,特别是在脂质体、脂质纳米颗粒或脂质胶束等脂质制剂中。脂质提供结构稳定性,增强药物溶解度,实现控释,并促进靶向药物递送。
● 荧光染料:也称为荧光团或荧光探针,是吸收一种波长的光并以更高波长发射的化合物,从而产生可见荧光。它们是生物学研究中的重要工具,用于标记和检测蛋白质、核酸和细胞等生物分子,从而在显微镜、流式细胞术和实时荧光定量 PCR 等应用中实现灵敏和精确的可视化。
● 点击化学试剂:具有高特异性和最少的副产物,简化了复杂的合成过程。因此,它们在分子生物学、材料科学和药物化学中发挥着至关重要的作用。
● 聚合物聚乙二醇:多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 可裂解连接子:一类重要的分子,广泛应用于药物发现、化学生物学和材料科学等各个领域。这些连接子充当两个或多个分子实体之间的连接桥,可以在特定条件下选择性地裂解,从而释放附着的分子。这一特性使它们成为生物活性化合物靶向药物递送、成像和控释的有吸引力的工具。
● 抗体及抗体-药物偶联物及细胞生物学试剂:种类丰富可选择。
● ADC有效载荷:作为 ADC 的三个主要成分之一,有效载荷是高活性和有毒的药物分子,通过化学连接子附着在抗体上。有效载荷可以是小分子、蛋白质毒素、生物活性肽、酶,甚至放射性核素。通过适当的接头与适当的载体系统耦合的有效载荷可能会显示出靶向药物递送的特异性和有效性的提高。
● 脱氧核糖核酸:DNA 是脱氧核糖核酸的缩写,是一种包含所有生物体发育和功能的遗传指令的分子。DNA 由四个基本组成部分组成,称为核苷酸,由糖、磷酸基团和含氮碱基组成。
● 改性剂:改变其他分子或材料特性的化合物。在药物研发领域,改性剂在新型药物递送系统和生物医学设备的设计和优化中发挥着至关重要的作用。一种常见的改性剂类型是官能团,它是赋予分子特定化学和物理性质的原子的特定排列。
● 探针:AxisPharm 提供各种靶标特异性探针,例如叶酸 PEG、生物素 PEG、PROTAC PEG、荧光染料探针和图像探针。探针是一类含有官能团的化合物,旨在选择性地与生物分子(如酶、受体和核酸)相互作用。这些官能团包括荧光染料、生物素和亲和标签等,可以检测和定量复杂生物系统中的特定分子。
| Different Types of Polyethylene Glycol PEG Linkers in Stock | ||||
| Acid PEG | Diketone PEG | Non-PEG linker | PFP ester PEG | Sugar PEG β-Glucuronide Linker |
| Aldehyde PEG | DNP PEG | PEG-t-butyl ester | Phosphonate PEG | Sulfonic acid PEG |
| Alkyne PEG | DBCO PEG | PEG-X-PEG | Polymer PEG | TCO PEG |
| Amino PEG | DSPE PEG | Peptide Linkers | Propargyl PEG | Tetrazine PEG |
| Aminooxy PEG | Fluorescent PEG | Lipid PEG | PROTAC Linker | Homobifunctional PEG |
| Azide PEG | Fmoc PEG | M-PEG | Silane PEG | Bromo PEG |
| BCN-PEG | Folate PEG | Maleimide PEG | SPDP PEG | Tosylate PEG |
| Benzyl-PEG | Thiol PEG | MeNH-PEG | Branched PEG | Bis-Sulfone PEG |
| Biotin PEG | Hydrazide PEG | NHS ester PEG | HyNic PEG | DOTA Reagent DOTA PEG |
| Bis-PEG-acid | Hydroxy PEG | Boc-PEG | Bis-PEG-NHS | Iodo PEG |
| Bis-PEG-NHS | Cleavable Linkers | |||
| Lipids for Drug Delivery | ||||
| Biotinyl Cap PE | Dodecanyl PE | Other Lipid | Phosphatidylcholine | Phosphatidylethanolamine |
| Biotinyl PE | Glutaryl PE | PDP PE | Phosphoglycerol | Ptd Thioethanol |
| Caproylamine PE | Ionizable Lipid | PE MCC | Phosphoserine | Succinyl PE |
| Cationic Lipid | Lipid PEG | Cyanur PE | MPB PE | |
| Fluorescent Dye | ||||
| AF Dyes | Cyanine Dyes | MB Dyes | Rhodamine Dye | Rox (carboxy-X-rhodamine) Dye |
| APDye Fluors | DNP PEG | JOE | R6G | Peptide Labeling Reagents |
| Bodipy Probes | Fluorescein (FAM) | Pyrene Probes | TAMRA Dye | Classic Fluorescent Dyes |
| IR Fluors | Quenchers | Coumarin 343 | ||
| Click Chemistry Tools & Reagents | ||||
| Alkyne PEG | BCN-PEG | PTAD Linker | Tetrazine PEG | Click Chemistry Auxiliary Reagents |
| Azide PEG | DBCO PEG | TCO PEG | Methylcyclopropene Linkers | |
| Polymer PEG | ||||
| Acrylate | Biotin | Fmoc | Lipoamide | Silane |
| Active ester | Boc | Folate | Maleimide | Stearic acid |
| Aldehyde | Carboxylic acid | guanlian1010 | MW 2000 | TCO |
| Amine | Cholesterol | Hydrazide | MW 5000 | Thiol |
| Azide | DBCO | Hydroxyl | Polysarcosine | |
| Cleavable Linkers | ||||
| -S-S-Cleavable | PC Cleavable | Disulfide Linkers | Dde Cleavable Linkers | β-Glucuronide Linkers |
| Cleavable Peptide | diazo biotin probes | DTSSP crosslinker | Photocleavable Biotin | |
| Antibody and Antibody Drug Conjugate (ADC) | ||||
| Inotuzumab | Trastuzumab | Enfortumab | Labetuzumab govitecan | Mirvetuximab soravtansine (solution) |
| Vobramitamab | Disitamab | Mirzotamab | Loncastuximab tesirine | Trastuzumab deruxtecan (solution) |
| Polatuzumab | Ozuriftamab | Brentuximab | Trastuzumab deruxtecan | ADC Control Human IgG1-Deruxtecan (DAR 8) |
| Gemtuzumab | Inebilizumab | Datopotamab | Cofetuzumab pelidotin | Glembatumumab vedotin |
| Daratumumab (PBS) | Denintuzumab | Sacituzumab govitecan | Belantamab mafodotin | Trastuzumab duocarmazine |
| Praluzatamab | Naratuximab | Tisotumab | Enfortumab vedotin-ejfv | Trastuzumab emtansine (solution) |
| Lorvotuzumab | Rolinsatamab | Trastuzumab emtansine | Telisotuzumab vedotin | Enfortumab vedotin-ejfv (solution) |
| Izeltabart | Mipasetamab | Datopotamab deruxtecan | Gemtuzumab ozogamicin | Brentuximab vedotin (solution) |
| Lupartumab | Iladatuzumab | ORM-5029 | Cantuzumab ravtansine | Depatuxizumab mafodotin |
| Cantuzumab | Briobacept | Ifinatamab deruxtecan | Tusamitamab ravtansine | ADC Control Human IgG1-Deruxtecan (DAR 4) |
| Lonigutamab | Tamrintamab | Tisotumab vedotin | Zilovertamab vedotin | Depatuxizumab MMAE |
| Moxetumomab | Sacituzumab | Disitamab vedotin | Polatuzumab vedotin | ADC Control Human IgG1-vcMMAF |
| Azintuxizumab | Upifitamab | Belantamab | Pivekimab | Sacituzumab govitecan (solution) |
| Lifastuzumab | Glembatumumab | Patritumab deruxtecan | Farletuzumab ecteribulin | |
| Payloads and Linker modified Payloads | ||||
| Exatecan | Belotecan HCl | SGD-1882 | Dolastatin 10 | MC-Val-Cit-PAB-Doxorubicin |
| SN 38 | Gimatecan | MMAF | Calicheamicin | Gly3-Val-Cit-PAB-MMAE |
| Amrubicin | Taltobulin | Auristatin E | Eribulin Mesylate | SuO-Glu-Val-Cit-PAB-MMAE |
| Mitomycin C | Dxd | Chlorambucil | Soblidotin (Auristatin PE) | Fmoc-G-amino-CH2O acetyl-Exetecan |
| Deruxtecan analog | Lurtotecan | PF-06380101 | Deruxtecan analog 2 | DM1-MCC-PEG3-Biotin |
| sulfo-SPDB-DM4 | Exatecan mesylate | Auristatin F | Paclitaxel | GGFG-amino-CH2O-acetyl Exetecan |
| Rubitecan | MC-DM1 | MMAF-methyl ester | MC-MMD10 | Mal-PEG8-Val-Cit-PAB-MMAE |
| (4-NH2)-Exatecan | Irinotecan | Doxorubicin-SMCC | SPDB-DM4 | DBCO-PEG4-Val-Cit-PAB MMAF |
| Topotecan | PNU-159682 | MMAD | 10-Hydroxycamptothecin | Topotecan Hydrochloride |
| CL2A-SN38 | DM4 | 7-Ethylcamptothecin | ||
| Cell Biology Reagents | ||||
| Neuro-DiO, lipophilic tracer | VU (5-Vinyl-uridine) | CM-DiI, lipophilic tracer | LumiTracker ER Green | ER-Tracker Red (BODIPY TR Glibenclamide) |
| Annexin V-AF 647 conjugate | DAPI, blue fluorescent nucleic acid stain | Propidium Iodide | Deep-Red Fluorescent Nissl Stain | MitoCLox, mitochondrial lipid peroxidation probe |
| Annexin V-AF 488 conjugate | LumiTracker Mito Rhodamine 123 | LumiTracker Mito Green FM | RAPID DiI, lipophilic tracer | Laurdan (6-Dodecanoyl-2-dimethylaminonaphthalene) |
| Annexin V, His Tag | Thiazole Orange | SynaptoProbe® Red | LumiTracker ER Red | Linear Polyacrylamide for Nucleic Acid Precipitation |
| DiD, lipophilic tracer | RH 237, potentiometric probe | SynaptoProbe® Green | RAPID DiO, lipophilic tracer | Fluo-4 AM, green fluorescent calcium indicator |
| DiR, lipophilic tracer | Hoechst 33342, blue fluorescent nucleic acid stain | LumiTracker® Mito Red FM | DiI, lipophilic tracer | YODi-1, green fluorescent nucleic acid stain |
| DNA | ||||
| CPG solid supports | DNA Stains | Modified Triphosphates | phosphoramidite | |
| Probes | ||||
| Biotin PEG | Folate PEG | Image Probes | PROTAC Linker | |
| Amine reactive Linkers | ||||
| Acid PEG | Aldehyde PEG | Bromo PEG | Maleimide PEG | NHS ester PEG |
▍AxisPharm提供的服务
● 蛋白质组学服务:提供质谱分析、蛋白质鉴定和定量服务。专注于生物标志物分析,帮助客户在复杂的生物样本中发现和验证潜在的生物标志物。
● 代谢组学服务:利用先进的LC-MS/MS技术进行代谢物分析,提供通路洞察,帮助客户理解代谢途径和生物过程。
● 高级LC-MS/MS服务:用于PK分析和HPLC分离,确保高精度和高效率的研究结果,提供PK/PD研究,支持药物开发和临床前研究。
▍AxisPharm部分产品列表
| Cat# | Name | M.W. | Purity |
| AP15197 | Exatecan | 435.45 | ≥98% |
| AP15072 | SN 38 | 392.4 | ≥95% |
| AP15226 | Amrubicin | 483.47 | ≥98% |
| AP15664 | Mitomycin C | 334.3 | ≥98% |
| AP15203 | 10-Hydroxycamptothecin | 364.35 | ≥95% |
| AP15204 | 7-Ethylcamptothecin | 376.41 | ≥95% |
| AP15210 | Rubitecan | 393.35 | ≥95% |
| AP15211 | (4-NH2)-Exatecan | 403.43 | ≥95% |
| AP15206 | Topotecan | 421.5 | ≥95% |
| AP15207 | Topotecan Hydrochloride | 425.5 | ≥95% |
| AP15202 | Belotecan HCl | 433.5 | ≥95% |
| AP15208 | Gimatecan | 447.5 | ≥95% |
| AP15227 | Taltobulin | 473.65 | ≥99% |
| AP15201 | Dxd | 493.48 | ≥95% |
| AP15209 | Lurtotecan | 518.56 | ≥95% |
| AP15196 | Exatecan mesylate | 531.55 | ≥98% |
| AP15200 | Deruxtecan analog 2 | 579.58 | ≥95% |
| AP15205 | Irinotecan | 586.68 | ≥95% |
| AP15224 | PNU-159682 | 641.62 | ≥98.24% |
| AP15220 | Soblidotin (Auristatin PE) | 701.98 | ≥95% |
| AP15225 | SGD-1882 | 725.8 | ≥98% |
| AP15213 | MMAF | 732 | ≥95% |
| AP15216 | Auristatin E | 732 | ≥95% |
| AP15311 | Chlorambucil | 304.21 | ≥98 |
| AP15219 | PF-06380101 | 743.01 | ≥95% |
| AP15214 | Auristatin F | 746 | ≥95% |
| AP15215 | MMAF-methyl ester | 745.99 | ≥98% |
| AP15187 | Doxorubicin-SMCC | 762.8 | ≥98% |
| AP15217 | MMAD | 771.06 | ≥98% |

艾美捷科技代理HMGBiotech品牌产品。
高迁移率族蛋白B1(HMGB1)是一种高度保守的核蛋白,广泛分布于哺乳动物细胞。随着其晚期促炎作用的发现,HMGB1成为近年来研究的热点之一。HMGBiotech是
一家专注于为HMGB领域的研究人员和公司提供试剂、服务的公司;值得注意的是,HMGBiotech公司,是目前位数不多的,生产HMGB1蛋白氧化还原变体的供应商。
HMGB1在基因组的组织和表达中具有多种功能:当细胞因损伤(病毒、机械或化学创伤、中毒)而死亡时,HMGB1 被释放并被附近细胞中的受体吸收。此外,处于严重
压力下的细胞甚至在死亡前会分泌HMGB1;存活的细胞会发出一系列反应 - 炎症 - 并试图替换死细胞并重建受损组织。HMGB1能够促进恢复和再生,;然而,过多的
HMGB1与脓毒症、关节炎、动脉粥样硬化和癌症转移有关。HMGBiotech主要产品包括:
(1)细胞
来自 Hmgb1 野生型和 Hmgb1 敲除细胞的对照细胞裂解物
Hmgb1敲除小鼠胚胎成纤维细胞
Hmgb2敲除小鼠胚胎成纤维细胞
(2)质粒
HMGB1 质粒
RAGE 质粒
(3)蛋白质试剂盒
HMGB1亚型试剂盒
(4)不含LPS的HMGB1重组蛋白
(5)稳定标记的蛋白质
HMGB1 15N 标记用于质谱和 NMR
用于核磁共振的 SDF-1 15N 和 13C
SDF-1 15N 用于质谱和 NMR
(6)抗体
ANTI HMGB1单克隆抗体
< " data-original="http://pbl.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理HMGBiotech品牌"> 艾美捷科技代理HMGBiotech品牌
艾美捷科技代理Matrigen品牌。
Matrigen是一家专注于智能水凝胶材料研发与生产的生物技术公司,其核心技术围绕仿生细胞外基质(ECM) 开发可精确调控物理化学特性的3D培养系统,为生命科学研究和再生医学提供革命性工具。

主要产品包括:
| Softwell 6 | Softview 35 / 10 Glass |
| Softwell 12 | Softview 35 / 20 Glass |
| Softwell 24 | Softslip 6 |
| Softwell 96 | Softslip 12 |
| Softwell 96 HTS | Softslip 24 |
| Softwell 6 Glass | Soft Islet |
| Softwell 12 Glass | Soft Slide 8 |
| Softwell 24 Glass | Soft Flask 25 |
| Softwell 96 Glass | Soft Flask 75 |
| Softwell 96 Glass HTS | Soft Flask 175 |
| Softwell 384 Glass | Soft Chamber 8 |
| Petrisoft 35 | Softcert 6 |
| Petrisoft 100 | Softcert 12 |
| Petrisoft 150 | Softcert 124 |
更多详情请咨询→

全国免费热线:400-6800-868
直拨专线:+86-027-59626688;18771997407
客服QQ一:17754422825;
客服QQ二:18771149750
公司地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋13
咨询和订购邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://pbl.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Aalto Bio Reagents品牌。
Aalto Bio Reagents 是一家专注于为诊断、疫苗和生物制药行业提供高质量生物试剂和原料的公司,提供病毒、细菌、激素、人源蛋白、肿瘤标志物、传染病的抗原和抗体。Aalto Bio Reagents 的产品广泛应用于传染病诊断、疫苗开发、生物制药和科学研究等领域。主要业务包括:
(1)诊断试剂原料:Aalto Bio Reagents 提供用于体外诊断(IVD)的生物试剂,包括抗原、抗体、血清和质控品。这些试剂支持传染病(如 HIV、肝炎、流感)、自身免疫疾病和癌症的诊断。
(2)疫苗开发原料:提供用于疫苗开发的生物原料,如病毒抗原、重组蛋白和佐剂。
(3)生物制药原料:Aalto Bio Reagents 提供用于生物制药生产的生物原料,如细胞培养添加剂、纯化试剂和分析标准品。这些原料支持单克隆抗体、重组蛋白和其他生物药物的生产。
(4)GMP 生产:Aalto Bio Reagents拥有符合 GMP(药品生产质量管理规范)标准的生产设施,能够为诊断、疫苗和生物制药行业提供高质量的生物原料。
<<<< " data-original="http://pbl.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Aalto Bio Reagents品牌"> 艾美捷科技代理Aalto Bio Reagents品牌
<艾美捷科技代理GenoSensor Corporation品牌全系列产品
GenoSensor Corporation是一家基因组技术公司,专注于为从事基因组研究和/或需要基因组解决方案的生命科学领域客户提供产品和服务。公司产品线包括:微RNA芯片、PCR/实时定量PCR(QPCR)试剂盒、基因组改变分析工具,DNA提取试剂盒以及临床应用的专用试剂盒及试剂。

▎GenoSensor Corporation产品线
● MicroRNA Expression Profiling
MicroRNA是约21个核苷酸(NT)的非编码小RNA,参与转录后调控,并在多种细胞和生物体中表达。GenoExplorer™ microRNA生物芯片和检测方法为研究microRNA表达及其谱分析提供了支持。microRNA芯片包括人、小鼠、大鼠、果蝇、秀丽隐杆线虫、拟南芥以及其他物种的芯片,GenoExplorer™微阵列以高重复性、高信噪比和高灵敏度为标志,展现出高品质性能。
| 货号 | 品名 | 产品描述 | 规格 |
| 1101C | GenoExplorer™ microRNA kit - human 4 | GenoExplorer™ microRNA chips, labeling reagent, hybridization buffer and washing solutions | 4 reactions |
| 1102C | GenoExplorer™ microRNA kit - human 20 | 20 reactions | |
| 1111C | GenoExplorer™ microRNA kit - mouse/rat 4 | 4 reactions | |
| 1112C | GenoExplorer™ microRNA kit - mouse/rat 20 | 20 reactions | |
| 1121C | GenoExplorer™ microRNA kit - C. elegans 4 | 4 reactions | |
| 1122C | GenoExplorer™ microRNA kit - C. elegans 20 | 20 reactions | |
| 1131C | GenoExplorer™ microRNA kit - Drosophila melanogaster 4 | 4 reactions | |
| 1132C | GenoExplorer™ microRNA kit - Drosophila melanogaster 20 | 20 reactions | |
| 1141C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 4 | 4 reactions | |
| 1142C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 20 | 20 reactions | |
| 1199 | GenoExplorer™ microRNA for other species | - | |
| 1301 | GenoExplorer™ microRNA array labeling kit | GenoExplorer™microRNA labeling kit | 20 reactions |
| 1302 | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | 4 reactions |
| 1201C | GenoExplorer™ microRNA cihp - human 4 | GenoExplorer™ microRNA chips and 2x hybridization buffer | 4 chips (4 arrays) |
| 1202C | GenoExplorer™ microRNA cihp - human 20 | 20 chips (20 arrays) | |
| 1211C | GenoExplorer™ microRNA cihp - mouse/rat 4 | 4 chips (4 arrays) | |
| 1212C | GenoExplorer™ microRNA chip - mouse/rat 20 | 20 chips (20 arrays) | |
| 1221C | GenoExplorer™ microRNA chip - C. elegans 4 | 4 chips (4 arrays) | |
| 1222C | GenoExplorer™ microRNA chip - C. elegans 20 | 20 chips (20 arrays) | |
| 1231C | GenoExplorer™ microRNA chip - Drosophila melanogaster 4 | 4 chips (4 arrays) | |
| 1232C | GenoExplorer™ microRNA chip - Drosophila melanogaster 20 | 20 chips (20 arrays) | |
| 1241C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 4 | 4 chips (4 arrays) | |
| 1242C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 20 | 20 chips (20 arrays) | |
| 1299 | GenoExplorer™ microRNA for other species | - | |
| 1401C | GenoExplorer™ microRNA probe set - human | 1 complete GenoExplorer™ microRNA probe set for human in 384-well plates | 500 pmol |
| 1411C | GenoExplorer™ microRNA probe set - mouse/rat | 1 complete GenoExplorer™ microRNA probe set for mouse in 384-well plates | 500 pmol |
| 1421C | GenoExplorer™ microRNA probe set - C. elegans | 1 complete GenoExplorer™ microRNA probe set for C. elegans in a 384-well plate | 500 pmol |
| 1431C | GenoExplorer™ microRNA probe set - Drosophila melanogaster | 1 complete GenoExplorer™ microRNA probe set for Drosophila melanogaster in a 384-well plate | 500 pmol |
| 1441C | GenoExplorer™ microRNA probe set - Arabidopsis thaliana | 1 complete GenoExplorer™ microRNA probe set for Arabidopsis thaliana in a 384-well plate | 500 pmol |
| 1499 | GenoExplorer™ microRNA for other species | 1 complete GenoExplorer™ microRNA probe set in 384-well plates | - |
| 1501 | 2x Hybridization buffer | 2x hybridization buffer with optimized salt and formamide | 5 x 1ml |
| 1502 | 2x printing buffer | 2x phosphate printing buffer pH 8.3 | 100 ml |
| 1503 | Blocking buffer | Blocking buffer (or Buffer S for GenoExplorer array kit) | 5 x 1ml |
| 1504 | Washing buffers | Washing buffer I and II (concentrated) | 120 and 50 ml |
● MicroRNA qRT-PCR Analysis
GenoExplorer™microRNA qRT-PCR试剂盒提供了一个简单且高灵敏度的工具,用于定量检测特定的miRNA。该试剂盒可测量miRNA的成熟形式或前体形式,或者同时测量两种形式。
<| 货号 | 品名 | 产品描述 | 规格 |
| 2001 | GenoExplorer™ miRNA qRT-PCR Kit-100 | Provides complete set for miRNA quantitation including first-strand cDNA synthesis and SYBR® Green I qPCR reagent mix. (primers not included, see Cat# 2003 and 2004) | 100 reactions |
| 2002-10 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-10 | Provides necessary core components to generate miRNA first-strand cDNA for miRNA expression quantitation. | 10 reactions |
| 2002-50 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-50 | 50 reactions | |
| 2003 | GenoExplorer™ miRNA qPCR Primer Sets | Provides specific primer pair for miRNA quantitation analysis (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and reference primer sets (Cat# 2004). Refer miRBase for available genes and primers. | 100 µl |
| 2004 | GenoExplorer™ miRNA qPCR Reference Primer Sets | Reference primer as an internal control reference (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and GenoExplorer™ miRNA qPCR Primer Sets (Cat# 2003).Selection of human-U6, human-U44, human-5SrRNA; mouse-U6, mouse-5SrRNA; rat-U6, rat-5SrRNA; Drosophila-U6 and 5SrRNA | 100 µl |
| 2005 | GenoExplorer™ 2X qPCR Mix | 2X SYBR® Green I qPCR mix, specifically for miRNA and small RNA amplification and quantification, containing all PCR reagents and polymerase | 750 µl |
● Gene Expression Profiling
GenoExplorer™ 基因表达谱分析生物芯片包括:针对选定基因及其可变剪接异构体的定制微阵列,涵盖人、小鼠、大鼠及其他物种的完整基因文库,以及用于表达研究的基因子集。
| 品名 | 产品描述 |
| GenoExplorer™ Human Genome Chips | Microarray contains 29K human microRNA sequences |
| GenoExplorer™ Human Functional Genomics Chips | Microarrays include the subsets of functional genes and ESTs, such as signal transduction, liver enzymes, etc. |
| Custom Chips | We will help you design your custom chips for the genes that you are interested in. |
● COVID-19检测试剂盒
GenoSensor开发了一种高灵敏度检测方法,利用实时逆转录聚合酶链反应(RT-PCR) 直接检测病毒基因组(RNA),具有操作简便和可实时检测得特点。
| 货号 | 品名 | 产品描述 | 规格 |
| 2702-22 | GS™ COVID-19 Real-Time PCR Kit - 30 | Provide all-in-one master mix including cDNA synthesis, PCR mix, primers and probe of each gene. | 22 samples |
| 2702-94 | GS™ COVID-19 Real-Time PCR Kit - 126 | 94 samples |
● QS™ DNA 提取试剂盒
QS™ DNA 提取试剂盒包含的试剂能够裂解细胞、使蛋白质变性,并保护核酸免受核酸酶和氧化作用的降解。该方法极其快速且简单,只需两步操作,即可从多种类型的组织和细胞中提取 DNA,提取的可直接用于 PCR 和测序分析,无需纯化步骤。
| 货号 | 品名 | 产品描述 | 规格 |
| QS8001 | QS™ DNA Extraction kit | Solution A (Lysis)100ml and Solution B (Balance) | 10ml |
▎GenoSensor Corporation提供的服务
● 基因组改变分析:包括多态性基因分型(如SNPs和STRs)、基因组结构分析、基因扩增与缺失分析以及基因组重排分析。
● 定制微阵列:根据提供探针化学物质,构建经过质量控制的阵列。临床应用:专门为癌症和心血管疾病开发和销售基因产品。
● 靶标制备:例如从组织、培养物和微生物中分离和纯化基因组DNA、质粒DNA和RNA。
● 靶基因扩增、定量和标记:提供基因扩增、产物定量和靶标标记服务。
● 测序:基因测序使用ABI测序系统进行。

艾美捷科技代理LifeSensors品牌。
LifeSensors成立于1996年,位于美国宾夕法尼亚州费城,是一家为药物发现与研究提供方法和可行性技术方法的生物技术公司。公司致力于为泛素和泛素蛋白酶体通路研究领域提供高品质
的抗体、酶、蛋白质等试剂和试剂盒,产品,是泛素研究者的好选择。
其原核和真核蛋白表达系统SUMOpro和SUMOstar已被世界范围内的学术、政府研究机构和制药、生物技术公司广泛应用。通过提供创新的研究工具,LifeSensors已成为泛素和泛素样蛋
白途径的优质供应商。
LifeSensors公司目前主要的产品有400多种,其产品主要覆盖泛素和泛素蛋白酶体通路等科学应用领域,并且产品线在不断的扩大中。公司开创了两大独家技术平台:用于细胞信号和药物
发现的泛素蛋白酶体系统(UPS),以及增强目的蛋白在大肠杆菌、酵母、昆虫和哺乳动物细胞中表达与纯化的SUMO融合表达系统。泛素蛋白酶体系统正在成为继激酶之后,药物发现的下
一个机遇,必将成为未来许多新型药物的创新来源。作为泛素蛋白领域的先驱公司,药物的发现、分析化合物以及去泛素酶和泛素化酶的高通量筛选正是LifeSensors创新技术的真正亮点。
此外,LifeSensors还为泛素的蛋白质组学提供众多定制技术服务,并且已经开发了各种各样的测定细胞中的生理底物或生物标志物的方法。
< " data-original="http://pbl.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理LifeSensors品牌"> 艾美捷科技代理LifeSensors品牌
Diapharma Group INC成立于1997年,研究人员具有多年临床以及研发经验,专注于血液病领域的试剂盒,试剂以及仪器,主要涵盖血栓形成、止血、血小板功能分析、细胞凋亡、生态毒理学等。"
Diapharma Group, Inc. in West Chester, Ohio sells hemostasis, thrombosis, platelet function testing, instrumentation, and apoptosis products in the diagnostic and research fields and provides strong technical competence and experience to ensure customer expectations will be met or exceeded.
DiaPharma Group的主要产品包括:
CK18 Biomarkers & Others
Apoptosis & Necrosis
Toxicology
Oncology
Hepatology
Hemostasis
Chromogenic Substrates
Coagulation Kits
Anticoagulation Monitoring Kits
Fibrinolysis Kits
Hemostasis Autoimmunity
Calibrators & Controls
Enzymes & Other Proteins
Buffers & Diluents
Factor Deficient Plasmas
Inhibitor Plasmas
Phospholipids
Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://pbl.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="diapharma"> diapharma

艾美捷科技代理Nanoanalytics品牌全系列产品
nanoAnalytics GmbH创立于1999年,是一家专业从事表面、界面和微观分析领域材料表征的公司,公司的主要产品包括全自动细胞跨膜电阻测量仪(CellZscope)以及cellQART耗材产品。该公司致力于为药物研发、毒理学、基础细胞生物学以及屏障功能研究提供强大的实时、无标记分析工具,以满足科研和工业界对体外细胞屏障模型功能定量评估日益增长的高标准需求。此外,NanoAnalytics公司还提供材料表征服务,运用尖端测量设备,实现微米至纳米量级的材料表面与界面分析。

▍cellZscope产品线
cellZscope®系列是专为非侵入式、自动化测量细胞层跨上皮电阻(TEER)和细胞层电容(Ccl)而设计的先进仪器系统。这些系统能够在模拟体内环境的生理条件下,对生长在多孔膜上的细胞层进行长期、连续且高度自动化的阻抗监测。其技术核心在于利用精密的阻抗分析技术,在尽可能不干扰细胞自然状态的情况下,获取反映细胞层完整性和功能的关键电生理参数。其具有以下特点:
● 提供精确的阻抗读数,兼容广泛使用的标准细胞培养耗材;
● 通过计算机软件实现便捷的数据记录、分析和实验控制;
● 不干扰细胞正常生长环境---测量的数值更加真实;
● 测量采用更宽的频率范围---拟合的数据更加精确;
● 构建的数理模型更加细致---电生理参数更加丰富。
| cZs E | cZs + | cZs 2 | cZs 3 | |
| Output parameters | TEER | TEER, Ccl | TEER, Ccl | TEER, Ccl |
| Number of wells | 6 | 24 | 24 | 24 (96§) |
| Supported insert sizes | 6-/12-/24-well | 6-/12-/24-well | 6-/12-/24-well | 6-/12-/24-well |
| Different insert sizes combinable | ✔ | ✔ | ✔ | ✔ |
| Works with standard cell culture inserts | ✔ | ✔ | ✔ | ✔ |
| Wells / Electrodes autoclavable | ✔ | ✔ | ✔ | ✔ |
| Measuring interval adjustable | ✔ | ✔ | ✔ | |
| High-speed measurement | ✔ | ✔ | ||
| Docking Station | ✔ | ✔ | ||
| Up to 4 Cell Modules per Controller | ✔ |
▍cellQART产品线
cellQART®是nanoAnalytics公司推出的一套专为配合其核心产品cellZscope®系统使用而设计的高品质、即用型耗材系统。cellQART®提供了多种规格的培养插板(Inserts),兼容标准的多孔板格式,其多孔膜材质(如 PET)和孔径大小经过优化,以满足不同类型细胞培养和精确阻抗测量的需求。
| 分类 | 货号 | Membrane Optics | Pore Size | Pore Density |
| 24-Well Inserts | 932 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 24-Well Inserts | 932 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 24-Well Inserts | 932 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 14 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 04 06 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 16 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 06 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 16 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 00 02 | - | - | - |
| 12-Well Inserts | 931 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 12-Well Inserts | 931 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 12-Well Inserts | 931 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 12-Well Inserts | 931 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 12-Well Inserts | 931 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 14 | clear | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 6-Well Inserts | 930 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 6-Well Inserts | 930 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 6-Well Inserts | 930 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 6-Well Inserts | 930 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 14 | clear | 1.0 µm | 2×106 /cm2 |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:17754422825
邮箱:sales@amyjet.com
0.2047